Ajax Therapeutics, Inc. clinical trials
Acquired by Eli Lilly and Company, Jun 10, 2026 · source ↗
The registry lists 1 studies whose lead sponsor is Ajax Therapeutics, Inc. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 12, 2026.
- 1study on the registry
- 1open to participants now
- 1reach primary completion within a year
Before and after it joined Eli Lilly and Company
- First submitted before Ajax Therapeutics, Inc. became part of Eli Lilly and Company
- 1
- First submitted after Ajax Therapeutics, Inc. became part of Eli Lilly and Company
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Coming up
1 of Ajax Therapeutics, Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- 1JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 1 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Open now1100%
Over the years
- 124
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company1 study
Something wrong with this grouping? Tell us on the Eli Lilly and Company page.
Studies
Recruiting first, then most recently updated. Showing 1 of 1. All Eli Lilly and Company studies →
- A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)RecruitingNCT06343805Phase 1
Sponsor listed in the registry: Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · First submitted before Ajax Therapeutics, Inc. became part of Eli Lilly and Company